AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +75

AbbVie Q1 Earnings Call Highlights

📈 AbbVie reported Q1 adjusted EPS of $2.65 and revenue of $15.0 billion, exceeding analyst expectations.

💰 Full-year adjusted EPS guidance was raised to $14.08–$14.28 with 2026 net revenue expected at approximately $67.3 billion.

🧬 Immunology portfolio showed strong momentum, with SKYRIZI generating $4.5B (+29%) and RINVOQ generating $2.1B (+20%).

🧠 Neuroscience products including VRAYLAR, the migraine portfolio, and VYALEV all posted double-digit growth gains.

💉 Phase III data for SKYRIZI in Crohn’s was positive, and an obesity candidate (ABBV‑295) showed nearly 10% weight loss at 12 weeks.

⚖️ AbbVie raised expectations for global SKYRIZI revenue to $21.6B and RINVOQ sales to $10.2B based on expanded indications.

🧠 Neuroscience total revenues were revised up to $12.6 billion, driven by momentum across the portfolio.

💊 Oncology revenues totaled over $1.6 billion, slightly down 3% operationally, with VENCLEXTA sales increasing 9.7%.

🧴 Aesthetics business revenue rose 5.1% to nearly $1.2 billion, led by a 17% increase in BOTOX Cosmetic sales.

⚠️ HUMIRA global sales declined 40.3% operationally due to biosimilar competition but remained within management expectations.

📉 R&D expenses included a $0.41 unfavorable impact from acquired in-process R&D, though adjusted gross margins remained at 83.6%.

✅ CEO Rob Michael described the quarter as an "excellent start" with performance exceeding expectations across the diverse portfolio.

🔬 Chief Scientific Officer Roopal Thakkar highlighted positive AFFIRM study data for SKYRIZI in Crohn’s disease induction.

Bullish Signals
  • AbbVie reported Q1 adjusted EPS of $2.65, which exceeded expectations by $0.07 above the midpoint of guidance.
  • Total net revenues reached $15.0 billion, beating analyst estimates by $300 million and reflecting sales growth of 12.4%.
  • Management raised full-year adjusted EPS guidance to a range of $14.08–$14.28, up $0.12 from the previous estimate.
  • CEO Rob Michael stated the company is 'off to an excellent start to the year' with performance exceeding expectations across its diverse portfolio.
  • Immunology segment drove strong growth with SKYRIZI reaching $4.5 billion in sales, up 29% operationally and gaining share in psoriatic and IBD indications.
  • SKYRIZI now expects global revenues of $21.6 billion, an increase of $100 million driven by demand growth in psoriatic and inflammatory bowel disease (IBD).
  • The FDA approved adding new results to the SKYRIZI label for genital and scalp psoriasis following data presented at the American Academy of Dermatology meeting.
  • RINVOQ global sales reached $2.1 billion, up 20.2% operationally, with a noted inflection in gastroenterology prescriptions for ulcerative colitis.
  • Neuroscience segment generated nearly $2.9 billion in revenue, up 24.3% operationally, with migraine portfolio growth driving the increase.
  • AbbVie raised expectations for total neuroscience revenues to $12.6 billion for the full year, an increase of $100 million.
  • RINVOQ sales expectations were raised to $10.2 billion globally, reflecting strong performance in rheumatology and gastroenterology.
  • Parkinson's therapy VYALEV is on track to become a blockbuster with sales of $201 million, up about 10% sequentially.
  • Oncology revenues showed resilience with VENCLEXTA sales reaching $770 million, up 9.7% operationally supported by emerging combination use.
  • AbbVie expects total net revenues of approximately $67.3 billion for 2026, an increase of $300 million from previous guidance.
  • The aesthetics business posted global sales of nearly $1.2 billion, up 5.1% operationally, with BOTOX Cosmetic revenue rising 17% to $668 million.
Risk Factors
  • AbbVie's HUMIRA global sales declined 40.3% operationally due to biosimilar competition, marking a significant revenue headwind despite expectations of being in line.
  • IMBRUVICA oncology product saw revenue decline 24.7% operationally due to IRA pricing reductions and competitive pressure in the market.
  • JUVÉDERM sales fell 2.9% amid continued headwinds in key dermal filler markets, attributed to lingering inflationary dynamics rather than a recession.
  • First-quarter adjusted EPS included a $0.41 unfavorable impact from acquired in-process R&D (IPR&D) expense, reducing reported profitability.
  • The full-year guidance does not include any estimate for acquired IPR&D expense that may occur beyond the first quarter, creating uncertainty about future quarterly results.
  • Neuroscience revenues expectations face potential risk as tavapadon faces a delayed timeline with a potential U.S. approval expected later in 2026 instead of immediate launch.
  • SKYRIZI phase III AFFIRM study data for Crohn's disease subcutaneous induction only met endpoints, requiring ongoing clinical validation to support expanded indications.
Full Analysis
AbbVie Inc. reported first-quarter 2026 results that significantly exceeded analyst expectations, with adjusted earnings per share (EPS) of $2.65 and total net revenues reaching $15.0 billion, representing a 12.4% increase year-over-year. CEO Rob Michael described the performance as exceeding expectations across the diverse portfolio, while CFO Scott Reents highlighted an adjusted EPS that was $0.07 above the midpoint of guidance. Notably, Reents specified that the first-quarter results included a $0.41 unfavorable impact from acquired in-process R&D expenses. Consequently, the company raised its full-year adjusted EPS guidance by $0.12 to a range of $14.08–$14.28 and updated expectations for 2026 total net revenues to approximately $67.3 billion. The primary driver of this commercial momentum was the strong performance within immunology, where SKYRIZI and RINVOQ posted substantial growth. SKYRIZI achieved global sales of $4.5 billion, a 29% operational increase, fueled by demand in psoriatic and inflammatory bowel disease (IBD) indications following FDA label expansions for genital and scalp psoriasis. RINVOQ sales reached $2.1 billion, up 20.2% operationally, with significant gains in gastroenterology prescriptions for ulcerative colitis. Conversely, HUMIRA global sales declined 40.3% operationally to $688 million, though this remained consistent with expectations given biosimilar competition. Beyond immunology, neuroscience and other segments demonstrated resilience. Neuroscience revenues nearly hit $2.9 billion, a 24.3% operational increase, driven by double-digit gains in the migraine portfolio (including UBRELVY, QULIPTA, and BOTOX Therapeutic) and growth in VRAYLAR. VYALEV, a Parkinson’s therapy, is on track to achieve blockbuster status with sales of $201 million. In oncology, total revenues were over $1.6 billion, down 3% operationally, as IMBRUVICA sales fell 24.7% due to IRA pricing and competition, though VENCLEXTA grew 9.7%. The aesthetics business reached nearly $1.2 billion in global sales; while BOTOX Cosmetic rose 17%, JUVÉDERM sales decreased 2.9% amid lingering inflationary dynamics in dermal filler markets. Looking ahead to the second quarter, AbbVie anticipates net revenues of approximately $16.7 billion with adjusted EPS between $3.74 and $3.78, excluding potential acquired IPR&D expenses beyond the first quarter. The company also highlighted significant pipeline progress, including positive Phase III data for SKYRIZI in Crohn’s disease (the AFFIRM study met endpoints), which supports a U.S. submission already under review, and obesity candidate ABBV-295 showing nearly 10% weight loss at 12 weeks. Regulatory submissions for Etentamig are now expected by the end of 2026, reinforcing AbbVie’s long-term growth strategy through business development and innovation.